NEW YORK, April 21 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc. The full 56-page report can be found at www.crystalra.com.
ACT Biotech, Inc. ("ACT Biotech" or "the Company") is a closely held pharmaceutical company focused exclusively on the development and commercialization of novel cancer therapeutics. Following a technology spinout from Bayer HealthCare LLC, ACT Biotech was founded with worldwide rights to a portfolio of in-licensed compounds that now compose four oncology programs. Each program demonstrates activity against a different set of molecular targets--including several kinases that are associated with cancer cell communication and growth--in order to inhibit various signaling pathways that are important in tumor development.
The Company's lead candidate, Telatinib, is a potent and highly selective oral tyrosine kinase inhibitor compound that targets pathways associated with the formation of tumor-related blood vessels (angiogenesis). While ACT Biotech has selected gastric (stomach) cancer as Telatinib's lead clinical target, the agent has also demonstrated solid potential as a drug candidate to treat colorectal, liver, and kidney cancers. In addition, based on its ability to readily combine at full dose with various standard-of-care chemotherapy regimens, Telatinib may have expansion opportunity to treat other major cancers, such as lung, breast, and prostate cancers. Gastric cancer is the second leading cause of cancer-related death worldwide with approximately 800,000 fatalities in 2007. It is also the fourth most common cancer, with over one million new cases diagnosed in 2007. The Company aims to initially develop Telatinib in two indications, gastric and colorectal cancer, with patient enrollment for a Phase II trial set to begin during the
|SOURCE Crystal Research Associates, LLC|
Copyright©2009 PR Newswire.
All rights reserved